As of 2025-01-22, the EV/EBITDA ratio of Oramed Pharmaceuticals Inc (ORMP) is -3.94. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. ORMP's latest enterprise value is 50.61 mil USD. ORMP's TTM EBITDA according to its financial statements is -12.85 mil USD. Dividing these 2 quantities gives us the above ORMP EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.4x - 9.8x | 8.3x |
| Forward P/E multiples | 13.0x - 18.7x | 16.4x |
| Fair Price | (3.10) - (2.08) | (2.89) |
| Upside | -234.7% - -190.6% | -225.7% |
| Date | EV/EBITDA |
| 2025-01-17 | -3.88 |
| 2025-01-16 | -4.00 |
| 2025-01-15 | -4.07 |
| 2025-01-14 | -4.13 |
| 2025-01-13 | -4.13 |
| 2025-01-10 | -4.22 |
| 2025-01-08 | -4.19 |
| 2025-01-07 | -4.32 |
| 2025-01-06 | -4.41 |
| 2025-01-03 | -4.38 |
| 2025-01-02 | -4.29 |
| 2024-12-31 | -4.32 |
| 2024-12-30 | -4.03 |
| 2024-12-27 | -4.16 |
| 2024-12-26 | -4.13 |
| 2024-12-24 | -4.19 |
| 2024-12-23 | -4.19 |
| 2024-12-20 | -4.16 |
| 2024-12-19 | -4.54 |
| 2024-12-18 | -4.25 |
| 2024-12-17 | -4.10 |
| 2024-12-16 | -4.22 |
| 2024-12-13 | -4.47 |
| 2024-12-12 | -4.54 |
| 2024-12-11 | -4.44 |
| 2024-12-10 | -4.60 |
| 2024-12-09 | -4.63 |
| 2024-12-06 | -4.25 |
| 2024-12-05 | -4.60 |
| 2024-12-04 | -4.63 |
| 2024-12-03 | -4.44 |
| 2024-12-02 | -4.46 |
| 2024-11-29 | -4.16 |
| 2024-11-27 | -4.16 |
| 2024-11-26 | -4.16 |
| 2024-11-25 | -4.10 |
| 2024-11-22 | -4.07 |
| 2024-11-21 | -3.97 |
| 2024-11-20 | -3.81 |
| 2024-11-19 | -3.94 |
| 2024-11-18 | -3.53 |
| 2024-11-15 | -3.72 |
| 2024-11-14 | -4.05 |
| 2024-11-13 | -4.00 |
| 2024-11-12 | -4.07 |
| 2024-11-11 | -4.00 |
| 2024-11-08 | -3.97 |
| 2024-11-07 | -4.19 |
| 2024-11-06 | -4.07 |
| 2024-11-05 | -4.10 |